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Abstract
The RNA polymerase NS5B of Hepatitis C virus (HCV) is a well-characterised drug target with an active site and four
allosteric binding sites. This work presents a workflow for virtual screening and its application to Drug Bank
screening targeting the Hepatitis C Virus (HCV) RNA polymerase non-nucleoside binding sites. Potential
polypharmacological drugs are sought with predicted active inhibition on viral replication, and with proven
positive pharmaco-clinical profiles. The approach adopted was receptor-based. Docking screens, guided with
contact pharmacophores and neural-network activity prediction models on all allosteric binding sites and MD
simulations, constituted our analysis workflow for identification of potential hits. Steps included: 1) using a two-
phase docking screen with Surflex and Glide Xp. 2) Ranking based on scores, and important H interactions.
3) a machine-learning target-trained artificial neural network PIC prediction model used for ranking. This provided a
better correlation of IC50 values of the training sets for each site with different docking scores and sub-scores.
4) interaction pharmacophores-through retrospective analysis of protein-inhibitor complex X-ray structures for the
interaction pharmacophore (common interaction modes) of inhibitors for the five non-nucleoside binding sites
were constructed. These were used for filtering the hits according to the critical binding feature of formerly
reported inhibitors. This filtration process resulted in identification of potential new inhibitors as well as formerly
reported ones for the thumb II and Palm I sites (HCV-81) NS5B binding sites. Eventually molecular dynamics
simulations were carried out, confirming the binding hypothesis and resulting in 4 hits.
Introduction
It takes too long and costs too much to develop a new
drug. Therefore, drug repositioning efforts are gathering
more attention (i.e., to screen available drugs for new
uses). Currently, fifty plus drugs have been repositioned
http://www.drugrepurposing.info/. Off-label uses of
drugs are widespread and legal in the USA. Also, multi-
targeting compounds have been used in various diseases
(e.g., receptor-thyrasine kinase inhibitors for various
cancers such as GleeVec and Nexavir [1,2]).
This study presents a workflow for virtual screening
and its application to Drug Bank screening targeting
the Hepatitis C Virus (HCV) RNA polymerase non-
nucleoside binding sites. Potential polypharmacological
drugs are sought with predicted active inhibition on
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viral replication. Hepatitis C virus (HCV) infects over
3% of the world population and is one of the leading
causes of chronic liver diseases [3]. About 80% of HCV-
infected patients develop chronic hepatitis, 20% progress
to cirrhosis and eventually develop Hepatocellular carci-
noma [4]. Currently there is no vaccine available for
HCV [5]. Current standard care of treatment for chronic
hepatitis C is based on the combination of subcutaneous
pegylated interferon-a and oral nucleoside drug riba-
virin. However, serious side effects and poor response
rates render the development of novel anti-HCV therapy
an urgent need [3,6]. Several clinical trials are currently
progressing for specifically targeted antiviral therapies
(STAT-C) inhibitors that target specific protein pockets
to inhibit HCV functions, while additional trials proceed
on compounds which target host cell proteins that the
virus utilizes for its survival/replication [7,8].
Currently, different targets for therapeutic intervention
include structural as well as non-structural proteins and
RNA structures in addition to post-transcriptional silen-
cing. Non-structural targets include the NS3 protease
covalent and non-covalent inhibitors, NS3-NS4A complex
inhibitors, NS3 helicase inhibitors, NS4B inhibitors, NS5A
inhibitors, nucleoside inhibitors and NS5B polymerase
non-nucleoside inhibitors. These were recently discussed
by Shimakami et al., [9] (and the included references). The
RNA-dependent RNA polymerase NS5B in particular has
been subject of intense research in the past decade
because of its essential role in viral replication, its distinct
features as compared to human enzymes, and ultimately
due to its highly druggable nature [10].
Although NS5B has the right-handed fingers, thumb and
palm domains typical of polymerases, extensions of the
fingers and thumb lead to a more fully-enclosed active site
[11] (Figure 1). The inhibitors of HCV NS5B polymerase
consist of two main classes: nucleoside inhibitors (NI) and
non-nucleoside inhibitors (NNI) [12]. The NIs bind to the
active site of the polymerase such as GS-7997, RGB7128,
TMC649128, PSI-7977 and PSI-938. They currently offer
the best candidates for cross-genotypic coverage and low
resistant mutants. NNIs are a structurally and chemically
heterogeneous class and do not induce premature termi-
nation of the RNA ssynthesis [13]. Moreover, NNIs are
almost invariably allosteric inhibitors believed to block the
enzyme, preventing a conformational transition needed for
initiation of RNA synthesis [14]; the fact that corre-
sponded with the results of Corbeil et al., [15] that
assumed a solvated, and essentially flexible receptor [16].
These NNI classes bind to one of the four allosteric bind-
ing sites within the NS5B polymerase (Figure 1) [17]
including: Site I (Thumb I) for JTK-109, benzimidazoles
and Indoles [18], Site II (Thumb II) for dihydropyrols,
phenylalanine analogs and thiophenes (PF-868554,
VCH-759, VCH-916 and VCH-222), Site III (Palm I) for
chemically heterogeneous leads such as ANA-598,
A-848837 and ABT-333, Site IV (Palm II) for benzofurans
as HCV-796 [19] and Site V (palm III) as phenylpropanyl
benzamides [20]. For details, refer to the methods and
results sections below and Figures 1,2, 3, 4, and 5 for a
schematic of the NS5B polymerase and is important resi-
dues for each NNI site in addition to the minimum inter-
action pharmacophore for some major classes of NNI
inhibitors.
Virtual Screening is the computational analogue of High
Throughput Screening. It is defined as the in silico evalua-
tion of properties, such as activity, or physiochemical
properties like drug-likeness of different molecular scaf-
folds. Different applications of machine learning to virtual
screening have been presented in the literature including
both ligand-based similarity searching and structure-based
docking. The main purpose of such applications is to
prioritize databases of molecules as active against a parti-
cular protein target. In silico approaches such as virtual
screening and structure-based design have emerged as a
reliable, cost and time-saving technique complementary to
in vitro screening for the discovery and optimisation of
leads and hits. VS can be divided into ligand-based, struc-
ture-based and mixed approaches such as the approach
implemented here (Figure 2). Activity-prediction/ranking
models could be based on the set of ligands only which
would be a purely ligand-based approach (such as the
pharmacophore for thePF-868554ligand set pharmaco-
phore built and shown in Figure 3). Or, it could be based
on the 3d structure of the ligand-receptor complex (inter-
action pharmacophore) (such as those shown in Figures 4,
5, 6 for the different NNI sites). The same holds true for
screening models which could be based on the ligand
pharmacophore/3D quantitative structure-activity rela-
tionship (3D QSAR); or it could be based on the score of
binding to the receptor (docking-based screen (as
employed here).
Attempts to perform focused screening on specialised
databases have been implemented before. These data-
bases include some whose compounds have acceptable
pharmacokinetic/pharmacodynamic properties (absorp-
tion, distribution, metabolism, excretion and toxicology)
(ADMET) properties. Virtual screening of physiochem-
ical properties as a first filter before activity-based
screening has also been highly recommended in virtual
screening protocols. It has been highlighted as a means
of preserving time, and money. This has been triggered
after the incompletion of a high percent of drug discov-
ery projects with good activity due to problems with
ADMET properties. Several studies have since indicated
the importance of such prefilters and considerations of
ADMET properties from the beginning. The SOCA
approaches made use of focused libraries of well-studied
compounds in terms of their pharmacokinetics for
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screening. Savarino et al., for example [21] using already
available drugs as multivalent compounds for other dis-
eases has been exploited for the HIV virus [22], for
example the chlorophyll and the or auranofin gold
nanoparticles. This has enlightened us to perform this
study for HCV. Samewise, several in silico studies have
been carried out previously from different perspectives
to explore drug promiscuity. Keiser et. al., [23] has used
Figure 1 A diagram showing the 3D structure of NS5B, showing key interaction residues (polar interactions; blue, hydrophobic;
green). The three different domains are shown (thumb; blue, palm; yellow, fingers; red).
Figure 2 A workflow describing the steps taken in both ligand-based and structure-based approaches to find novel inhibitors for HCV
polymerase NS5B. A) the ligand-based search consisted of pharmacophore generation and screening, followed by docking and selection.B)
Structure-based NNI work flow consists of identifying the target binding sites and their interaction pharmacophore, a two-stage docking screen,
combined with a neural-network ranking model for the hits, and finally, molecular dynamics simulations for the promising hits.
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molecular similarity measures to find new targets for old
drugs with experimental validations. Also, microarray
profiles of drugs have been successfully used for drug
repositioning efforts to new diseases [24]. Here, a struc-
ture-based docking approach is used to find promiscu-
ous drugs/compounds from the drug bank that could
target the HCV polymerase allosteric sites. This short
cut approach has yielded candidate hits that can imme-
diately enter into clinical trials for dosage determination
with minimal cost, pharmacokinetic, and toxicological
profiling studies, which could offer a potential of
improving treatment outcome with HCV chronic
patients [25,26].
Both Ligand-based and receptor-based drug design
approaches have been heavily implemented in finding new
candidate inhibitors for HCV polymerase [11,14,27-32].
Yet to date, a comprehensive docking-based virtual
screening of the Drug Bank for finding novel multivalent
compounds has not been performed, although several stu-
dies reported the use of high throughput docking for lead
identification and optimisation [14,16,33]. Furthermore,
the combinations of docking tools that are based on higher
accuracy scoring functions such as the XP (extra preci-
sion) and constrained docking approach in Glide were
used to filter off potential false positives from the initial
screening (Table 1). This was followed by molecular
dynamics-based investigation of binding profiles of the
resulting hits as detailed below.
Validation of the docking and selection was performed
in multiple steps. These included reproducing the origi-
nal interactions of the reference enzyme-ligand com-
plexes, comparing the root-mean square distance of the
experimentally determined pose with the docked pose,
and correlation of the enzymologic inhibition concentra-
tion (IC) 50/90 with the docking scores and sub scores.
These validations for choosing the higher accuracy score
for filtration were performed on datasets of known NNI
binding sites inhibitors obtained from the Binding DB
[34] in order to use the highest correlating score in the
filtration of initial hits. Extending this idea further, here,
we describe a neural-network artificial intelligence model
that was constructed to provide better correlations of
docking scores with experimental data through a target-
trained model. The model is based on a multitude of
scores and sub-scores from different scoring functions
for each binding site. These are combined non-linearly
via an artificial neural network classifier, that was used
here for ranking the hits obtained from first-phase dock-
ing with Surflex (Table 2 and Additional files 1, 2, 3, 4).
It could be later used after some statistical validations for
Figure 3 Thumb II dihydro pyrol inhibitor (Filibuvir) pharmacophore used for screening several databases. Its features are: A and B: two
methyl groups and C: cyclopentyle group as well as D: one hydrogen acceptor E: The enol/ketone oxygen of the dihydropyrone and F: one
other hydrogen donor and acceptor (The lactone carbonyl of the dihydropyrone).
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screening massive compound databases. These multiple
validation approaches were necessary in order to build
confidence in the final predicted compounds to have
novel inhibitory potential against the HCV polymerase.
We are currently working on the experimental validation
of these hits and extending this protocol.
Thus, through this work, novel inhibitors for the RdRp
of HCV are sought. Combinations of ligand-based,
receptor-based and incorporation of machine-learning
classifiers were introduced along with molecular
dynamics experiments to investigate the prospective
inhibitors. Also, a meta-retrospective analysis to gener-
ate common contact pharmacophores that represent
features required for efficient binding to NNI-sites for
the HCV RdRp was performed by collecting all PDB
files for each site, and finding common physical interac-
tion moieties that are shared across all inhibitors of the
same class that target that site.
For justification of our receptor-based approach, a
ligand-based pharmacophore was built on a promising
lead that is currently in clinical trials, Filibuvir (PF-
00868554), targeting the thumb II site. This was used to
screen different chemical databases with a few hits
retrieved that need more activity and ADMET profile
characterisation. These resulting hits were then short-
listed using the docking approach. In the structure-based
Figure 4 Interaction pharmacophore of three NNI binding sites compiled from structural superpositionand alignment of relevant PDB
coordinates for thumb I (A), palm II (B) and palm III (C), respectively. The essential interactions shown are described in the results section.
A) shows formation of hydrogen bond with ARG503 side chain and a hydrogen acceptor from the ligand B) HCV-796 inhibitor interacts with
both side-chains of SER 365 -forms hydrogen bond with a hydrogen donor- and ARG200, in addition to arene-cation bond between the latter
and the aromatic benzene ring of the benzofuran nucleus and H-bond donar with ASN 306 (not common for all pdb) C) The pocket seems to
be narrow and only two polar interactions were computed with residues: ASN316 and TYR195, showing a tightly closed proximity contour with
almost no solvent exposure by the ligand.
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screening, a refined docking, ranking, and validation
approach that employed machine-learning classification
during the ranking process was performed for all sites of
the RdRp on the drug bank database. The structure-based
approach relied initially on virtual high-throughput dock-
ing of the drug bank on the four allosteric sites yielding
tens of potential hits. This was followed by a second stage
of more rigorous docking for the top candidates resulting
from the former stage. Between them, ranking using the
ANN model was applied. Also, validation using IC correla-
tion for first-stage and rmsd for second-stage was done.
Hit binding analysis selecting top poses and use of the
interaction pharmacophores generated for each site fol-
lowed. Further testing through molecular dynamics simu-
lations culminated in potential hits acting on the palm I
and thumb II were concluded that scored higher than
threshold reference drugs, had low predicted IC values,
and stable binding poses with molecular dynamics.
The results and discussion sections will organise the
work as follows: Figures 1,2, 3, 4, and 5. These show a
schematic of the HCV polymerase (Figure 1), a schematic
of the workflow (Figure 2), a pharmacophore for the
thumb II site (Figure 3), and interaction consensus phar-
macophores for all NNI sites (Figures 4 and 5). Other
figures and tables illustrate the hits from different sites
and their scores and modes of binding (Figures 6, 7, 8),
Tables 1, 2 and Additional files 1, 2, 3 and 4. The final
three figures show the molecular dynamics runs for the
reference compounds and our potential hits (Figures 9, 10,
11). The ANN-models built using the external dataset and
their applications are illustrated in Table 2 and Additional
files 2, 3, 4.
Methods
The flowchart in Figure 2 depicts the steps implemented
in this study. Firstly, an interaction pharmacophore was
generated for each NNI binding site to reveal essential
interactions for each site. Secondly, a two-stage docking
screen on the drug bank was implemented with increasing
computational and time expense. A neural network model
for predicting activity based on the docking scores was
used for ranking the resulting hits. Finally, molecular
Figure 5 Interaction pharmacophore for the Palm I subdomain. Overlay of PDB coordinates of the three major chemical classes of NS5B
palm I inhibitors A) class I (Benzothiazoles), B) class II (Benzo thiadiazines), C) class III (Benzodiazepines)). D) Overlaid complexes at the thumb II
site (green dotted lines show polar interactions, different coordinates are colored differently, partial receptor surface is colored according to the
interpolated charge-showing the whitish neutral regions)(polar hydrogens displayed in section C) all classes for Palm I shown in A, B, and C fill
the deep hydrophobic pocket and shared TYR448 as a backbone HB acceptor. A) ASP318 also had polar interactions at the backbone. SER556
and ASN291 had hydrogen bond (HB) interactions through the terminal hydroxyl and amide groups with all members of class I.B) ASP318,
GLY449 and ASN 291 were also involved in the same manner in addition to the terminal polar groups of SER 556 and CYS 366.C) shows that
replacing the ketone on the hexene ring by a sulphone group expands the hydrogen bonding from TYR448 to TYR448 and GLY449, additionally,
SER 367 HB seemed a common feature and to a lesser extent SER368. D) The main residues forming common polar interactions were SER476,
TYR477 -as backbone HB acceptors and ARG 501 through the guanidinium group. A well defined π stacking was noticed between the histidine’s
imidazole ring and the filibuvir’s (3FRZ ligand) triazolo pyrimidine group.
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dynamics simulations and comparison with the interaction
pharmacophore was used for statistical validations of
the resulting compounds. A ligand-based pharmacophore
for the thumb II site (Figure 3) (which is a shallow site
that could benefit more from a hybrid ligand and struc-
ture- based approaches) was used for searching diverse
chemical banks and for comparison with the interaction
pharmacophore.
HCV polymerase allosteric binding-sites interaction
pharmacophores generation
Finding the minimum requirements for efficient binding
to all NNI-sites for the HCV RdRp was performed by
collecting various PDB files for complexes at each site
with different inhibitors, and finding common electro-
static/hydrophobic interactions that are shared across all
inhibitors of the same class that target each site. Due to
the large numbers of inhibitors used here, it was not
possible to site all reference works of these inhibitors.
However, we list the PDB codes and method of compar-
ison below:
Thumb I: All available thumb I inhibitors (e.g. benzi-
medazoles [35]) crystal structures in PDB were obtained
(PDB ID: 2BRK, 2BRL, 2DXS, 2WCX, 2XWY, 3MWW)
Palm I: Three main chemical classes were discerned for
the Palm I site, nominally: beznothiazoles (PDB ID:
3D5M, 3H5S, 3H5U), benzothiadiazines (PDB ID: 3CWJ,
2FVC, 2GIQ, 3BR9, 3BSA, 3BSC, 3CDE, 3CO9, 3CVK,
3E51, 3G86, 3GYN, 3H2L, 3H59, 3H98, 3HHK) and ben-
zodiazepines (PDB ID: 3CSO, 3GNV, 3GNW, 3GOL)
Palm II Site: The PDB files 3FQK and 3FQL com-
plexes with the HCV-796 inhibitor in both coordinates.
Palm III site: obtained from the PDB file 3LKH.
Thumb II: Some of the crystal structures of polymer-
ase and thumb II site inhibitors (PDB ID: 2HWH,
2HWI, 1YVZ, 3HVO and 3FRZ).
A protocol that utilizes Align123 to align protein
sequences then superimposes the protein structures by
the alignment (based on Ca carbons) was used to super-
impose the PDB files (Average RMSD was approximately
0.6 Å) for common binding modes visualization of each
site, with different PDB coordinates coloured differently.
Figure 6 A) Overlay of docked and PDB coordinates of 2JC1 ligand for the Palm I site (original ligand pose coloured blue, docked
ligand pose coloured pink); B) docked pose of DB05039 it shows a very good placement of the diethyl-indanyl group into the deep
pocket. A salt bridge strengthens the binding with ARG394. Similarly, hydrogen bonding with ARG386 and TYR415, and Pi stacking with TYR415;
C) docked pose of DB01940 forming a HB inside the deep hydrophobic pocket (as with one of benzodiazepines) in addition to a HB with
GLN446 (just four atoms away along the backbone’s TYR448 amidic nitrogen); D) docked pose of DB04142.(red dotted lines represent salt
bridges, green dotted lines represent hydrogen bonds, orange solid lines represent π-interactions, backbone shown as curved purple lines,
protein transparent surface with interpolated charges; bluish(+ve), reddish(-ve)). The furan ring show similar interaction with TYR448. These three
hits preserved these binding modalities after molecular dynamics simulations.
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Analysis of the common hydrogen interactions, electro-
static interactions and hydrophobic common moieties
was curated manually and revealed crucial information
about the modes of binding of different classes of the
HCV NS5B polymerase NNI inhibitors. These should be
very useful for future HCV NS5B drug discovery efforts.
The interaction pharmacophore for each site is illustrated
below in the results section and shown in Figures 4 and
5. The structure-based docking protocol was used to
check for the presence of those interactions in the highly
scoring hits.
Ligand preparation
Initially ligands were prepared using the ‘Prepare Ligands’
protocol in Discovery Studio 2.5 in order to standardize
charges, enumerate ionization states and generate tauto-
mers at physiological pH range (where chirality and gen-
eral conformation were preserved). The ligands were
typed using the CHARMM for partial charges set up all-
atom CHARMM force field (version 35b1) (Momany-
Rone partial charges method) [36]. The latter operation
was followed by a minimization through 1000 Smart
minimizer algorithm steps down to a RMS gradient less
0.05 kcal⁄mol⁄Å to 0.05 kcal/mol/Å in Generalized Born
implicit solvent model [37] to filter out the energetically
less stable ionic/tautomeric states, eventually selecting a
single molecular structure per ligand. (Partial charges were
replaced upon retyping at particular docking stages).
Ligand-based screening
For finding Novel candidate inhibitors for HCV virus
polymerase protein we took two different approaches:
pharmacophore-based approach using a pharmacophore
model built on the structure activity relationship of the
guide leads, and a receptor-based approach by screening
of the Drug bank on the different polymerase binding
sites. The pharmacophore screening was performed on
the thumb II site (Non-nucleoside inhibitor site), using
the Structure Activity Relationship (SAR) of the experi-
mentally active ligand set pf-00868554 [38], respectively.
The built models were used in virtual screening against
four different chemical databases: the NCI database [39],
the Maybridge Hit-Finder [40], drug bank [41] and ZINC
databases [42] using the MOE program.
Table 1 Docking scores and interactions for all NNI binding sites of hits structure against polymerase receptor with
glide program using extra precision mode (hits with asterisk were selected for the molecular dynamics stage).
NNI Site XP score Pi interactions Salt bridges HB Compound
Palm region -8.5195 TYR415 (π-π) ARG394 ARG386
TYR415
DB05039*
Palm region -8.27362 - - GLN446
SER368
DB01940*










Palm region -7.0822 - ARG394 SER368
TYR448
DB04142*




Palm region -6.93098 - - TYR448 2JC1 ligand*
Palm region -6.5971 - - CYS366 DB01203
Palm region -4.64441 TYR415 (π-π) ASP318 GLN446
ASN316
DB01888
Thumb II -7.80905 HIS475 (π-π) ARG501
SER476
3FRZ ligand*
Thumb II -6.9871 - - LEU497 DB00450
Thumb II -6.28764 HIS475 (π-π) - SER476 DB04859
Thumb II -6.01285 - - SER476 DB00481
Thumb II -5.82026 - LYS533
ARG501
TYR477 DB04205*




Thumb II -3.17019 TRP528 (s-π) - ARG501
LEU474
DB00816*
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Table 2 NS5B Palm inhibitors dataset from Binding DB training and correlation of different scores and of neural-network model (PIC).
Drugbank ID Sybyl Total score D_SCORE PMF_score G_score cscore Glide_xp_score glide_constrained MOE IC50 “-Log IC50” Predicted IC50
BindingDB_50139657 4.88 -111.015 -25.9954 -194.009 5 -6.18107 -7.46377 -11.2018 1000 -3 -3.405
BindingDB_50139665 3.38 -83.8017 -10.2113 -143.318 2 -5.72753 -7.42372 -12.3084 12000 -4.07918 -4.433
BindingDB_50139675 5.58 -106.188 -13.164 -158.077 5 -6.70348 -7.21041 -10.7057 2000 -3.30103 -2.717
BindingDB_50139676 5 -107.152 -11.3032 -158.959 1 -6.88072 -7.15086 -11.0469 1400 -3.14613 -3.09
BindingDB_50139677 4.27 -94.9065 3.964 -135.671 2 -6.40549 -7.13436 -11.3156 32000 -4.50515 -3.663
BindingDB_50139678 5.5 -114.532 -0.6873 -198.09 4 -6.76792 -6.89594 -10.9051 1500 -3.17609 -3.338
BindingDB_50139679 5.69 -104.815 -9.0235 -158.517 3 -6.1566 -6.88072 -11.313 50000 -4.69897 -5.371
BindingDB_50139680 4.95 -105.057 -12.5186 -145.938 5 -7.13436 -6.76792 -11.0915 34000 -4.53148 -4.862
BindingDB_50139681 4.64 -101.361 -2.2207 -151.314 2 -7.42372 -6.70348 -10.5949 2000 -3.30103 -2.717
BindingDB_50139682 5.37 -114.286 -22.6751 -146.53 5 -6.28327 -6.6221 -11.5046 1200 -3.07918 -2.157
BindingDB_50139683 5.08 -123.814 -25.821 -170.98 4 -7.46377 -6.41286 -11.1089 1200 -3.07918 -2.157
BindingDB_50139684 5.76 -109.545 -21.031 -175.899 2 -4.65519 -6.40549 -11.207 5000 -3.69897 -4.044
BindingDB_50139685 3.97 -121.737 -2.4307 -185.222 5 -7.21041 -6.28327 -11.1865 21000 -4.32222 -3.111
BindingDB_50139686 3.27 -113.558 -18.1067 -186.234 4 -6.41286 -6.18107 -11.4439 9000 -3.95424 -4.074
BindingDB_50139687 4.74 -96.1194 5.4162 -152.586 5 -6.89594 -6.1566 -11.2615 50000 -4.69897 -4.097
BindingDB_50139688 4.17 -107.649 -14.0725 -155.075 4 -7.15086 -5.72753 -10.883 3000 -3.47712 -3.65
BindingDB_50139689 5.4 -105.728 -12.6317 -155.943 5 -6.6221 -4.65519 -10.8427 50000 -4.69897 -3.964
Pearson Correlation 0.184765 -0.42111 -0.50627 -0.35705 -0.09258 -0.08262 -0.35147 0.23712 -0.92744 1 0.68



















Successful candidates were filtered using molecular
docking; first, the receptor preparation was performed by
addition of hydrogens and dehydration of the crystalliza-
tion water molecules using the program default para-
meters. The docking was performed using “triangle“
matcher as placement and “londonDG“ for scoring and
force field refinement. Identification of the binding site
was performed using MOE’s “Site finder” tool. ADMET
properties were obtained for the highest scoring hits of
the active site. Primary in-silico ADMET properties were
Figure 7 A) Overlay of docked and PDB coordinates of 3D5M ligand(original ligand pose coloured blue, docked ligand pose coloured
pink), B) docked pose of DB0056 showed H-bond donor with CYS366 and SER367 and h-bond acceptor with LYS 155 and ASP 319.
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predicted using the pharma algorithms ADME-TOX
Boxes server (the server was free and latter commercia-
lized). to determine Oral bioavailability, Absorption,
Distribution, Solubility, And using Tox Boxes to deter-
mine Acute Toxicity (LD50, Mouse) and Acute Toxicity
(LD50, Rat).
Receptor-based screening
For finding Novel candidate inhibitors for HCV virus
polymerase protein with acceptable ADMET profiles,
our approach was screening of the Drug Bank database
[41] for new candidates at the polymerase’s different
binding sites. For each site we have identified from the
PDB five publicly available crystal structures of polymer-
ase bound to different ligands representing the different
binding sites (3MWW for an indole-based inhibitor
[43], 2JC1 for Acyl pyrolidine inhibitors [44], 3D5M pyr-
idazinone inhibitor [45] and 3FRZ [38] dihydropyran
inhibitor) of the non-nucleoside inhibitors, mainly tar-
geting the thumb I, thumb II and the palm region.
Those four structures were used as reference leads to
guide the screening protocol of the Drug Bank database
using Surflex-Dock and also for validation of docking.
The crystal structure files of polymerase NS5B co-crys-
tallized with different ligands were downloaded from the
PDB.
A two-phase docking was performed to filter the candi-
dates, The first stage was performed using SYBYL X1.1
Surflex-Dock program(Tripose Inc) virtual screening
mode [18] where the protein receptor was prepared by
removing the unrelated substructure other than the
ligand structure. Ligand structures were extracted and
isolated in separate files. The side chains of the protein
structure then were fixed using default settings, water
atoms removed, hydrogen added, unknown atom types
were assigned and bumps were relaxed. The Kollman-all
atom charges were assigned to protein atoms. Finally, the
whole structure underwent a staged minimization using
the default parameters. The Surflex Scoring is based on
the Hammerhead scoring function and a consensus score
that is the linear combination of non-linear functions of
protein-ligand atomic surface distances. The interactions
include steric, polar, entropic, and solvation terms. In
addition, a total score is also generated. At this stage
scores were compared between the docked compounds
and the original ligand’s SYBYL total score. Only those
with total score equal to or higher than the positive con-
trol’s score for each site were accepted.
The potential candidates scoring higher than the con-
trol were subjected to the second phase of filtration using
Glide [18]. Receptor pre-processing was performed by
removing water molecules of crystallization among other
Figure 8 A) Overlay of docked and PDB coordinates of 3FRZ ligand(original ligand pose coloured blue, docked ligand pose coloured
green) for the thumb II site, B) docked pose of DB04205 it showed salt bridging with ARG501 & LYS503; C) docked pose of DB01087
it showed salt bridging with ARG501 & LYS503; D) docked pose of DB00816 it showed salt bridging with ARG 501 & LYS503.
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pre-processing provided by “preparation and refinement”
utility in Schrodinger package. The extra precision (XP)
Glide method was used to dock the potential hits derived
from SYBYL into their respective allosteric sites of HCV
NS5B polymerase. The binding sites, for which the var-
ious energy grids were calculated and stored, are defined
in terms of dimensions forming the enclosing box, which
must contain all ligand atoms of an acceptable pose.
They were defined according to the original inhibitor
centroid and expanded to include any extra-residues that
are reportedly significant for the respective site. Poses
with a root-mean-square deviation (rmsd) of less than
0.5 Å and a maximum atomic displacement of less than
1.3 Å were eliminated as redundant to be able to increase
diversity in the retained ligand poses. Poses retained for
initial docking were doubled from the XP default
(10,000) with extended sampling, also in-situ minimiza-
tion rounds were quadrupled (400 steps) in order to
increase the robustness and remove any unfavourable
contacts in the final poses.
Docking validation
Validation is the most important part for a successful
drug design protocol. Several steps of validation were
performed. The following methods were used:
1) The different scoring functions of used programs
were correlated to the IC50 of experimentally deter-
mined inhibitor sets. So, we used structure sets from
binding database [34] of known experimental activ-
ity. They were docked and scored using each scoring
function. The correlation between the enzymologic
IC50 of the structures and different scoring functions
were calculated.
2) Another validation approach was performed by
testing for the capability of the programs used to
reproduce poses and interactions of sufficient simi-
larity to the original crystal structure. This criterion
was measured by calculating the root mean square
deviation (rmsd) difference between the docked and
the PDB coordinates of the co crystallised inhibitor
for each site.
Machine-learning target-trained model for efficient
IC50 prediction
An Artificial Neural Network (ANN) model capable of
predicting the IC50 for drugs targeting HCV polymerase
thumb II binding site is proposed and implemented here.
Chemical structure and IC50 of the PF-868554 and its
related structures were obtained. Scoring of the com-
pounds using various tools like SurFlex [18], Gold [19],
Glide, and MOE followed. The features to build the classi-
fier were based on the different docking scores and their
components. The idea was to combine these scores non-
linearly to attain a predicted activity. These experimental
data were then split into training and validation datasets
and as the training data was small we used cross-validation
technique to evaluate our model, using WEKA version
3.7.1 (Waikato Environment for Knowledge Analysis,
Figure 9 RMSD across time along the production phase for the
three protein ligand systems of the three PDB coordinates in
the order: 2JC1 (palm), 3D5M (palm), 3FRZ (thumb II) (top to
bottom).
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University of Waikato, and NZ) [46]. This model was then
applied to rank and filter the virtual hits for this site based
on (PIC50 of our candidate drugs and evaluate them.
Due to the wide range variability of the IC50 between the
drugs, we applied - log IC50 (PIC50) instead of IC50. We
did a comparative study between various tools outputs
Figure 10 Hydrogen bonds count formed between the ligand and receptor molecules across the production phase trajectory. The
plots represent the systems of NS5B structure complexed with the original PDB ligand coordinates and docked hits coordinates (at the palm
region) in the order: 2JC1, 3D5M, DB05039, DB01940, DB00560, DB04142 (left to right, top to buttom).
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including GOLD, GLIDE, MOE and SYBYL; to select the
proper parameters to build our model, based on the corre-
lation coefficient between each set of parameters and the
experimental PIC50 (Table 2 Additional files 1, 2, 3, 4).
Molecular dynamics
The GROMACS 4.5.4 package [13] was used for all of
the simulation and analysis of the molecular dynamics
experiments. Initially protein structures were cleaned
Figure 11 Hydrogen bonds count formed between the ligand and receptor molecules across the production phase trajectory. The
plots represent the systems of NS5B structure complexed with the original PDB ligand coordinates and docked hits coordinates (at the thumb II
region) in the order: 3FRZ, DB04205, DB01087, DB00816 (left to right, top to bottom).
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from non-protein non-ligand atoms, then the topology
files were generated for the protein and ligand separately
using the GROMOS96 43A1 force field and the
PRODRG tool [40] respectively. The system was created
by manually including the ligand topology into the sys-
tem’s, followed by configuring a dodecahedron box of a
margin of 1 nm in all directions, which was filled with
water using the SPC explicit solvation model. The net
charge of the system was then neutralized by adding
chloride ions, thus rounding up to around 60,000 atoms
per system.
Minimization was carried out through 100,000 steps
with a convergence criterion of maximum gradient of
500 kJ/mol/nm by the steepest descent algorithm.
Force constant of 1000 kJ/mol/nm, two temperature
coupling groups were created (protein and ligand, water
and ions), and the modified Brendsen thermostat was
hence used for both of the equilibration phases. Each of
the NVT (where the system temperature was raised up to
300K) and NPT equilibration phases were 150 ps long
(pressure coupling was isotropic, using the Parrinello-
Rahman method).
For all of the runs (including the equilibration phases)
the leap-frog integrator was used for force calculations
with the Particle Mesh Ewald method used for electro-
statics calculations, and time step of 2 fs. Finally, the pro-
duction phase was conducted -where the system was
fully unrestrained- for 5 ns for each complex, the trajec-
tory of which was target of all of the analytical procedure
reported herein. All these steps were performed using a
multitude of tools available in the GROMACS package.
The production phase was computed through the MPI-
aware version of MD run executable at a Sun Microsys-
tems cluster, deploying 40 (8 threads each) nodes,
accounting a net of 1.4 petaFLOP per run, kindly provided
through the library of Alexandria super computer system.
Results and discussion
Several drugs have been recently repositioned for other
diseases in the market, with up to two thirds of the costs
being cut during the drug discovery course since only
phase II clinical trials were the starting point. The promis-
cuity of compound binding, and the multi targeting strat-
egy are being explored for different purposes and the old
paradigm of one key one lock is being changed. This could
also be due to the limited space of folds and binding pock-
ets in proteins that are chosen by nature, and the similarity
of binding/different binding preferences that one com-
pound can make.
Pharmacophore-based virtual screening
In the first phase of our work, we consider only a
ligand-based approach to find new candidates for HCV
targeting the polymerase protein. The Structure Activity
Relationship (SAR) obtained from “pf-008654” was used
for building of the pharmacophore model for the thum-
bII site. The pharmacophore of the PF-868554 features
are (Figure 3): the enol/ketone oxygen of the dihydropyr-
one which appear to form a direct hydrogen bond to the
backbone amide NH of Ser-476 and a water-mediated
hydrogen bond to the amide, also NH of Tyr-477 (the
donor-donor motif). The lactone carbonyl of the dihydro-
pyrone is involved in a water mediated hydrogen bond to
Arg-501. The phenol functional group forms another
hydrogen bond with Leu-497 through a water molecule,
while the phenyl ring occupies an otherwise hydrophobic
pocket. [Figure 3 shows the features of the pharmaco-
phore on the PF008654 ligand].
The screening of the databases Drug bank, Maybridge
and zinc databases yielded no significant structures while
the NCI database yielded two significant hits. The hits
were subjected to further analysis through docking with
Surflex and Glide achieving significant docking scores.
The thumb II best hits NSC 115863 and NSC 295688)
which by docking scored (-18.803 and -16.119 respectively
but with no hydrogen bonds for the NSC 115863 and one
water bridge hydrogen bond for the NSC 295688). This
motivated us to implement a more rigorous virtual screen-
ing method using structure-based design after understand-
ing the essential binding requirements as shown below.
Polymerase NNI binding-sites essential interactions
pharmacophores
Inspection of the interactions and binding modes of dif-
ferent classes of molecules that have exhibited strong
inhibitory activities to different HCV polymerase binding
sites was carried out, which provides a better insight
into the essential residue interactions for each NNI site
(Figure 1 shows a 3D structure diagram of the NS5B
domains and their key residues).
Thumb I: Ligand interactions were calculated and it was
noticed that the residues that form the pocket are MET36,
VAL37, ALA396, LEU392, ALA393, ALA395, THR399,
ILE424, LEU425, HIS428, PHE429, LEU492, GLY493,
VAL494, PRO495, TRP500, ARG503. Figure 4-A shows
how important is formation of hydrogen bond with
ARG503 side chain and a hydrogen acceptor from the
ligand as all structure share the same interaction. In addi-
tion, resistance towards benzimidazole thumb I inhibitors
was reported upon mutations at PRO495 position [47].
Palm II: The phamacophoric features were observed
from the interaction of HCV-796 inhibitor with both
receptor’s side-chains of SER365 -forms hydrogen bond
with a hydrogen donor- and ARG200, in addition to
arene-cation bond between the latter and the aromatic
benzene ring of the benzofuran nucleus (Figure 4-B). In
3FQK the ligand forms a hydrogen bond (HB) with
ASN316 which is not present in the structure 3FQL due
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to replacement of ASN with CYS. This substitution
seemed to significantly affect the binding, suggesting that
HB an essential interaction (bearing in mind that position
316 already affords natural sequence polymorphism). The
S365T mutation seemed to be equally disruptive to the Kd
(fold-shift > 200) as well. The pocket is formed of the fol-
lowing residues LEU204, LEU314, VAL321, LEU360,
ILE363, SER365, ASN369 and the overlapped part with
palm I site with residues MET193, PRO197, ARG200,
ASN316, CYS366, SER368, LEU384, MET414, TYR415
and TYR448.
Palm I: From analysis of binding of the ligands of the
aforementioned crystal structures, the ligands were cate-
gorized according to the three largest chemical classes
of inhibitors co-crystallized with protein; class I (ben-
zothiazoles), class II (benzothiadiazines), and class III
(Benzodiazepines) which each bind to the palm I site in
different modes. The site is at the junction of the thumb
and palm domains and in proximity of the active site
(similarly palm II and palm III), the pocket is formed of
the following residues GLN184, MET193, PRO197,
ARG200, THR287, SER288, ASN291, ASN316, GLY317,
ASP318, CYS366, SER368, LEU384, GLY410, ASN411,
MET414, TYR415, GLN446, ILE447, TYR448, GLY449
and SER556, these residues show partial overlap with
palm II site in the following residues MET193, PRO197,
ARG200, ASN316, CYS366, SER368, LEU384, MET414,
TYR415 and TYR448.
From Figure 5 it seems obvious that all of the inhibitor
classes fill the deep hydrophobic pocket, as also described
as an important binding feature by Vandyck et al., [14]. It
is also thought to afford the most substantial Van der
Waal interaction energy contribution and confers an
important selectivity character. Point mutations at
MET414 [48,49] (which forms a major portion of the deep
hydrophobic pocket) resulted in resistance against ben-
zothiadiazines. On the other hand, there are diverse polar
interactions among the classes in addition to few common
ones. In particular, the amino acid TYR448 as a backbone
HB acceptor has been proven to play a critical role regard-
less of the chemical class. This fact was established
through molecular dynamics simulations showing the free
energy decomposition for different residues performed by
Li et al., [50] and by point mutation studies at 448 [49]
which again resulted in benzothiadiazine-resistant
mutants. ASP318 also had polar interactions at the back-
bone. SER556 and ASN291 had hydrogen bond (HB)
interactions through the terminal hydroxyl and amide
groups with all members of class I shown in Figure 5. For
class II ASP318, GLY449 and ASN291 were also involved
in the same manner in addition to the terminal polar
groups of SER556 and CYS366. Lastly, for class III it
seemed that replacing the ketone on the hexene ring by a
sulphone group expands the hydrogen bonding from
TYR448 to TYR448 and GLY449, additionally, SER367
HB seemed a common feature and to a lesser extent
SER368.
Palm III: To date only a single PDB coordinate set was
reported and deposited, showing the inhibitory potential
of phenylpropyl-benzamides at the recently observed palm
III. The key interaction residues were found to be
TYR195, PRO197, ARG200, LEW384, MET414, TYR415,
ASN316, ILE447, TYR452, LEU446, TRP550, and
PHE551. The pocket seems to be narrow and only two
polar interactions were computed (Figure 4-C) with resi-
dues: ASN316 and TYR195, the figure shows a tightly
closed proximity contour with almost no solvent exposure
by the ligand.
Thumb II: The thumb II site is clearly distinct from the
thumb I site and each site has its separate residues, thumb
II site is formed from the following residues (LEU419,
ARG422, MET423, HIS475, SER476, TYR477, ILE482,
VAL485, LEU497, LEU489, ARG501, TRP528, and
LYS533), it lies at the base of the thumb domain around 35
Å from the active site (Figure 5-D). The main residues
forming common polar interactions were SER476, TYR477
-as backbone HB acceptors- and ARG501 through the gua-
nidinium group. A well defined π stacking was noticed
between the histidine’s imidazole ring and the filibuvir’s
(3FRZ ligand) triazolopyrimidine group. Other inhibitor-
specific hydrogen bonding was noted by the residues
LYS533, TRP528, ARG422 and MET423 (it is noteworthy
that 419 and 423 mutations exhibited viral selection against
thiophene-based carboxylic acid derivatives [51]). The inhi-
bitor on which the ligand-based pharmacophore model
was based (Figure 3)afforded direct polar bonding with
SER476, ARG501 and Van der Waal interaction through
the cyclopentyl moiety (with the shallow pocket formed of
TRP528, MET423, LEU419 and TYR477) also π-π interac-
tion with HIS475.
Based on this retrospective analysis, the analysis per-
formed seemed to be consistent with results shown above
from single point mutagenesis studies in confirming some
predicted key interaction residues. Particularly important
are ASN316, SER365, TYR448 and MET414 are at the
palm region, LEU419 and MET423 at the thumb II site.
Receptor-based screening
The screening of the drug bank on the three sites specified
using Surflex-Dock yielded several potential binders; those
compounds were subjected to our two-phase docking
using SYBYL then Glide, as described earlier. In SYBYL
we selected the ones exceeding the control threshold score
(the experimentally proven ligands). Several candidates
were found targeting the three sites on HCV polymerase,
twelve compounds targeting NNI site I, ten compounds
targeting NNI site II, five compounds targeting NNI site
III, while for thumb I no significant hits were achieved
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from score prospective. On the second docking phase we
used Glide extra-precision (XP) docking to further filter
our candidates.
First stage filtration with SurFlex
Different ligands of proven activity/affinity against the
polymerase which came co-crystallized with polymerase
receptor and bound to its different binding sites were
separated and re-docked into polymerase protein. The
mean of the docking scores of these ligands was used as a
threshold for first phase filtration of the screening results
of the drug bank on the different sites of the polymerase
receptor. This process resulted in 84 high scoring struc-
ture ligands that exceeded the threshold of 8 of Surflex-
Dock total score. They were arranged as 19 structure for
thumb II site, 12 structure for palm I site, 52 structure
for palm II site (Additional file 1) while no structures
succeeded to cross the filtration threshold in thumb I,
interestingly we noticed that 9 structures of high scoring
drugs showed potential activity against more than one
binding site which are (DB01166, DB01036, DB04859,
DB00918, DB04471, DB01087, DB06202 and DB00481)
two of these drug, DB01036 and DB04859 achieved high
scores for three binding site which are (palm I, palm II
and thumb II) with scores of (8.62, 8.03, 8.03 for
DB01036) and (8.58, 8.02, 8.24 for DB04859) in the three
binding sites respectively, also DB01166 appears to bind
at the palm I site with a score of 12.16 while DB04471
appears to bind to palm II and thumb II with the scores
9.65 and 9.36.
Upon screening the drug bank, DB01166 achieved
highest score; 12.16, then the compounds DB00777,
DB04471, DB05039, DB02166 and DB04205 with scores
9.98, 9.36, 9.23, 9.19 and 8.83 respectively (Table 2).
On the other hand the further filtration process based
on consensus of scores of many docking programs which
were incorporated in one machine learning model
(described in the methods section) has helped in the selec-
tion and correlation with enzymologic IC. According to
the model results, the correlation was improved slightly
using the model for the thumb II site (from 0.86 to 0.87)
and significantly for the Palm I site (from 0.5 to 0.67
(Table 2 and Additional files 2,3, and 4). The model was
then used for ranking the filtered hits based on the pre-
dicted IC values. The domain of applicability of the
neural-network model here was used only for ranking, as
the idea of a machine-learning model based on docking
scores as features was not implemented before. We will
seek to expand this model in terms of a docking-based
workflow and machine-learning filtration in the future to
be applied to diverse chemical databases. Many of these
drugs have proven good affinity against RDRP. The
DB01940 which achieved the highest score for palm I site
driven from the model the potential binding mode
proposed by surflex shows that the azocane ring of the
structure fixes the structure to the pocket B while forma-
tion of 4 hydrogen bonds two of them are the same
formed by the original ligand which are ASN411, Gly449
and two other hydrogen bonds with each of Tyr415 and
Tyr448, while on the molecular fields level fair similarity
of the hydrophobic molecular field to the original ligand
was noticed. We were encouraged by the identification of
some known HCV polymerase inhibitors among the
retrieved hits (e.g.: HCV-086 in Additional file 1), which
gave us more confidence in the work flow and methodol-
ogy that we have proposed. Now, these eighty six filtered
compounds were advanced to a second round of filtration
as detailed below.
Second stage filtration with XP Glide docking
While no potential final list candidates were found for
the thumb I site; several candidates that fulfil the inhibi-
tory pharmacophoric requirements for the thumb II site,
and the palm region were found. The next phase of
docking was performed using the Schrodinger Glide
module version 5.5, in particular, implementing the
CPU-expensive Glide XP docking function which has
resulted in satisfactorily low RMSD differences upon re-
docking the co-crystallized inhibitors (please refer to the
validation title in the introduction point 2 for details).
Consequently from the resultant hits only 7 compounds
were selected according to their affinity and mode of
binding for the final molecular dynamics simulation.
For the palm region, docking of the co-crystallized
ligand resulted in a pose with a RMSD of 1.2 Å and 1.09 Å
calculated from superposition of heavy atoms of the
docked ligands over the crystal coordinates for PDB coor-
dinates 2JC1 and 3D5M respectively. Through retrospec-
tive inspection, the top four ranking hits were selected for
further analysis as they bare a relatively rich electrostatic
interaction profile as well as sufficiently high Van der
Waal interaction XP terms with the receptor. The rest of
the hits showed very weakly interacting poses and Glide
XP scores lower than that of the co-crystallized -report-
edly potent- inhibitor [44,45] (except for DB04118 and
DB01888).
The original ligand of 2JC1 (Figure 6-A), as in the crystal
structure, had a docked pose exhibiting a single hydrogen
bond with the TYR448 residue, which suggests the suffi-
ciency of that bonding - in addition to filling the deep
hydrophobic pocket with the p-tert-butyl phenyl group -
as a criterion for inhibition at this site. Worth noting is
the improved field positioning for the carboxyl group of
the docked pose right amid the two guanidinium groups
of ARG394 and ARG386, that might have happened
because we haven’t minimized the PDB structures before
superimposition. In spite of the relatively low RMSD value
for superposition of the docked and original poses of
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3D5M ligand (Figure 7-A), the docking result gives a bet-
ter preposition of a possible proton exchange between the
sulphonamide of the ligand and the ASP318 carboxyl, and
yet again hydrophobic moiety (the di halo-substituted
phenyl in this case) fell very well into the deep pocket
(Figure 7-A).
Though realizing the highest docking score, hit
DB05039 did not interact with any of the common polar
interactions discussed, yet it shows a very good placement
of the diethyl-indanyl group into the deep pocket (Table
1). A salt bridge strengthens the binding with ARG394.
Similarly, hydrogen bonding with ARG386 and TYR415,
and Pi stacking with TYR415. DB01940 followed in terms
of score, interestingly enough with an azepane ring form-
ing a HB inside the deep hydrophobic pocket (as with one
of benzodiazepines) in addition to a HB with GLN446
(just four atoms away along the backbone’s TYR448 ami-
dic nitrogen) (Figure 6-C). Hence, both of the formerly
mentioned ligands were found to be of interest, and may
potentially define new pharmacophoric features.
The hit DB00560 ranked third (Table 1) with a glide
score of -8.073859 and achieved the highest electrostatic
energy contribution of all with three hydrogen bonds and
two salt bridges with the receptor, superseding the origi-
nal ligands in terms of coulombic interaction term as
well as total score, although it seems to possess a differ-
ent positioning than the other hits, the structure was pro-
tonated from predocking processing at the secondary
amine, which was the reason why the tert-butyl place-
ment failed inside the hydrophobic pocket (Figure 7-B).
Albeit the compound already satisfies two of the com-
mon interactions discussed, namely with CYS366 and
SER367.
In comparison between the pose of hit DB04142 and
that of the original ligand (Figure 6-D), we find a similar
placement, similar TYR448 interaction, a significantly
enriched electrostatic field complimentarity with the site
features, even less unfavourable ligand solvent exposure,
and obviously less expected conformational entropy. The
docking score lied well between those of the two original
ligands.
While for Thumb II the main trend of ligand-receptor
interaction observed from the docked set was mainly
comprised of the Van der Waal terms -the contributed to
most of the total binding energy- with many unfavour-
able solvent-surface exposure, yet in the contrary to the
palm region the hydrophobic of thumb II is quite shal-
low, the fact that down weighs such terms. Most of the
set exhibited minimal electrostatic interaction (in most
cases a single hydrogen bond was observed), nevertheless,
π interactions were common (especially with TRP528,
due its annular residue proximity).
An RMSD of 0.78 Å was obtained upon re-docking the
original ligand of 3FRZ. The overlaid poses are shown in
Figure 8-A where the docked pose seemed to have shifted
slightly to form HB acceptor and donor -to TRP528 and
ARG501 respectively- out of the hydroxyl group instead
of a double acceptor -from ARG501.
Only 3 ligands (DB04205, DB01087, DB00816) were
observed to possess better binding modalities (Figure 8),
including salt bridging with ARG501 & LYS503, along
with hydrogen bonding with the protein’s backbone at
different residues albeit minimal. Also π-π, s-π interac-
tions were observed (Table 1), while they recorded the
highest coloumbic energy terms. The three compounds
were candidates for further investigation though molecu-
lar dynamics simulations for a sufficiently long produc-
tion phase. In spite of the prospected good binding
properties of DB04205, it seems to be highly hydrophilic
and thus not expected to be effective in vivo as is. So a
pro-drug strategy is required during the biological assays.
Also the stability of DB00816 inside the binding site was
questionable due to improper positioning of group and
the apparently promiscuous nature of the hit as a non-
selective ligand due to the relatively small size.
From these two stages of docking screens and ranking,
some interesting compounds have emerged that will be
taken into molecular dynamics simulations as the next
and final step in this protocol. These compounds belong
to diverse structural classes, highlighting one advantage of
the structure-based approach. Some of them also satisfy
some of the interaction pharmacophoric features that
were identified, while others show new binding modalities.
Molecular dynamics simulations
For a stronger hypothesis and a better insight into the
validity of the docking results achieved, we have con-
ducted coarse-grained molecular dynamics simulations
for the formerly mentioned selected group of ligand-pro-
tein complexes that were the result of the two-phase
docking and selection phases using the GROMOS force
field. It was performed in the form of 20 ns of unrest-
rained production phase dynamics, following a double
equilibration period 300 ps long where constant tempera-
ture (298.15 K) and pressure (1 atm) were imposed. The
Ca RMSD was calculated and plotted for all of the sys-
tems starting from the end of the equilibration phase.
Since all of the systems have produced similar plots in
terms of time to RMSD stability tendency beyond the
2500 ps interval, Figure 9 shows Ca RMSD for only the
three original systems derived from the PDB coordinates
taken as control. Resultant interaction patterns were
inspected after a post-production minimization process.
Also confirmation of positional and conformational ten-
dency from minimized average structures sampled from
the last 1 ns of the simulation (500,000 frames) was
regarded. For brevity, only 5NS are shown in Figure 9. In
Figures 10 and 11, the HB count along the trajectory are
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shown to illustrate the strength and stability of the differ-
ent specific HB interactions of the hits in comparison to
reference ligands.
In general the control ligands of the palm region
showed a preserved placement (Figure 10 shows HB pat-
tern along the trajectories of palm site complexes), 2JC1
had alternating interactions between ARG386 and
TYR448, while for 3D5M a minor backbone rotation has
led to hydrogen bonding with SER556, GLN446, and
additional TYR448 contact, also two new π-interactions
were noticed inside the hydrophobic pocket (π-π with
TYR415 and cation-π with ARG386) in a manner baring
more resemblance to the original PDB coordinates
(rather than the docked one).
A conserved mode was noticed for hit DB05039 as its
hydrophobic contact which evolved into more subtly
relaxed rotomer was preserved, also the π-π interaction
with TYR415, while the an extra HB was formed with the
latter. Moreover, DB01940 has undergone significant con-
formational changes around the site releasing some strain
to a more extended conformation, the conformational leap
could be noticed in the form of a transient sharp increase
in HB count around 2.7 ns, new HB with TYR448,
SER556 and a cation-π with ARG158, and less frequently
with hydrogen bonding with GLY557 and VAL284.
Calculating the average structure proved that although
hit DB00560 possesses a seemingly favourable hydrogen
bonding trend, yet the hydrophilic nature of the hit has
led to a sufficient binding liability and more favourable
ligand-solvent interactions. Notably hit DB04142 has
undergone slight rotation to reorient forming an average
of 3 hydrogen bonds 2 of which with the TYR448 (the
most commonly redundant pharmacophoric feature
amongst the analysed PDB’s), SER368 and GLN446.
The results of the dynamics simulations for the thumb II
site were inherently different due to its nature. The hydro-
gen bonding pattern seemed very labile owing to the
extensive solvent exposure and the shallowness of the
binding site, hence the obvious lower density of the resul-
tant HB contacts along the ensemble (Figure 11).
The HB count of hit DB04205 (Figure 11) seems to
have dropped suddenly by the end of the first 2.5 ns of
the production phase, where a transient partial binding
has taken place at the edge of the site hinged through the
two phosphate groups till beyond the 4.5 ns, then the
ring -by the end of the 5 ns interval- has flipped outwards
to form new hydrogen bonds with the surface residues
ARG380 and LYS379.
DB01087 has exhibited a very stable trend of hydrogen
bonding (Figure 11). Albeit around an average of 1.6 HB,
the compound formed two additional π interactions;
nominally s-π with ALA529, and π-π with ARG501 thus
sandwiching the substituted electron-rich quinoline scaf-
fold. On the contrary, and as expected hit DB00816 failed
to prove any appreciable binding properties and was gra-
dually expelled towards the edge of the binding site.
Thus, from the discussion above, hits DB05039,
DB01940, and DB04142 (Figure 6B, C, and 6D show
their binding poses and interactions, and Figure 10
shows their Hydrogen bond stability along the MD
simulation) would be expected to bare an inhibitory
potential against NS5B at the palm region, while for the
thumb II site only DB001087 (Figure 8-C) would be
prospected to bare an inhibitory potential from amongst
the other hits. These virtual hits are currently experi-
mentally tested on the HCV replicon system as well as
enzymatic assays.
Conclusion
The goal of the receptor-based workflow was to identify
potential NS5B inhibitors through virtually screening of
the Drug Bank database, followed by hit refinement
through another more computationally stringent docking
stage. Selected hits and three inhibitors from palm and
thumb II sites have been subject to 20 ns of explicit-
solvent, fully unrestrained molecular dynamics simula-
tions, for which binding patterns were analysed to obtain
an insight considering various physical factors -mainly
receptor flexibility and solvent effects (Figures show 5NS
for brevity). As a result the hits were better characterised
according to their binding capabilities and modalities.
Eventually, four different hits were recognized to exhibit
sufficiently favourable binding properties to be prospected
as potential inhibitors of NS5B.
We have generated the common trends of receptor-
ligand interactions pharmacophores, calculated from 37
PDB coordinates compiled according to the corresponding
sites. Categorizing the palm region into three sub-sites, it
seemed that hydrogen bonding with the backbone amide
of TYR448 and hydrophobic interaction with the deep
pocket were found to be a common binding feature
among all chemical subclasses of palm I inhibitors, also
polar interaction with ASN316 was common between
palm II and palm III inhibitors. While SER476, TYR477
and ARG501 polar contacts constituted the major features
for thumb II inhibitors, ARG503 formed the only common
polar interaction for thumb I inhibitors. These “essential”
interactions that have been defined here constitute a
method of selection that could be used in various virtual
screening exercises on the NS5B protein. This concept of
polypharmacology could be utilised for various new drug
discovery endeavours. Reuse of already available safe com-
pounds should thus shorten and lower the expenses of the
long drug discovery cycle.
The novel idea of basing a machine-learning activity
prediction model on interaction simulation scores was
used here for ranking the retrieved hits from first-stage
docking with Surflex. It could be further improved as a
ElHefnawi et al. BMC Bioinformatics 2012, 13(Suppl 17):S5
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screening tool, or including essential pharmacophoric
interaction data as features in the future.
Additional material
Additional file 1: Docking Scores and interactions for all NNI
binding sites using Surflex-Dock hits across all site sorted in
descending order according to Surflex-Dock total score.
Additional file 2: HCV NS5B ThumbII Binding DB and another
dataset training and correlation of different scores and of neural-
network model (PIC). The model improved the correlation to0.87.
Additional file 3: Neural-network Model implementation on Palm I
candidates obtained from Surflex screening on the drug bank.
Additional file 4: Neural-network model implementation on Thumb
II candidate hits obtained from first-stage screening with Surflex
docking.
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